Thanks for registering
We encountered a previous register of this Medical ID. An email has been sent for instructions to activate this account.
Welcome to Abbott platform
A code was sent to you via email, please insert the verification number
En nuestra base de datos encontramos un registro previo.
Se ha enviado a tu correo electrónico un email para activar tu cuenta.
No se pudo validar su cuenta.
test.
BIOSIMILARS
June 9, 2025
Abbott has a long and proud 135-year history of delivering safe and effective medicines, including biologic products.
| Date | |
| Over 100 years ago | Our scientists create a first-generation biological medicine in small capsule form. These capsules release tiny spheres – called Minimicrospheres® – which contain enzymes similar to those produced by a healthy pancreas to digest fats, proteins and other food elements. This remains a vital medicine for many people with conditions where the pancreas doesn’t release enough digestive enzymes, such as cystic fibrosis or pancreatic cancer. |
| 1900s | Abbott manufactures and sells an inactivated biologic vaccine that is still one of the top-selling flu vaccines in emerging countries. |
| 2000s | Abbott launches the first fully human monoclonal antibody therapy, which has become one of the most successful and widely used biologic medicines in the world, revolutionizing the treatment of autoimmune diseases including rheumatoid arthritis, psoriasis, and Crohn’s disease. |
| 2010s | Abbott delivers a range of biosimilars for several types of cancer, such as breast cancer, colon cancer, and certain types of blood cancer (like non-Hodgkin’s lymphoma). |
| 2020s | Abbott launches a biosimilar for osteoporosis in India, offering a more affordable high-quality option for osteoporosis, bone loss, and prevention of cancer-related bone pain and fractures. Abbott announces an agreement with global biotech leader mAbxienceHoldings S.L. to commercialize several biosimilars in Latin America, Southeast Asia, the Middle East and Africa. |
| Present day | Today, Abbott continues to work with global and local partners to expand access to biosimilars in emerging countries, helping to ensure more people benefit from these life-saving treatments. |